


## Thalidomide-O-C6-NHBoc

<b>Cat. No.:</b>	HY-141887
<b>CAS No.:</b>	2509093-23-4
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>31</sub> N <sub>3</sub> O <sub>7</sub>
<b>Molecular Weight:</b>	473.52
<b>Target:</b>	E3 Ligase Ligand-Linker Conjugates
<b>Pathway:</b>	PROTAC
<b>Storage:</b>	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (211.18 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	2.1118 mL	10.5592 mL	21.1184 mL	
5 mM	0.4224 mL	2.1118 mL	4.2237 mL	
10 mM	0.2112 mL	1.0559 mL	2.1118 mL	

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Thalidomide-O-C6-NHBoc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

Cereblon

### REFERENCES

[1]. Daniel A. HARKI, et al. Compounds that degrade kinases and uses thereof. WO2020247537A1.

[2]. Zhang NN, et al. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020;182(5):1271-1283.e16.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA